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SUMMARY
Metabolic reprogramming provides critical informa-
tion for clinical oncology. Using molecular data of
9,125 patient samples from The Cancer Genome
Atlas, we identified tumor subtypes in 33 cancer
types based on mRNA expression patterns of seven
major metabolic processes and assessed their clin-
ical relevance. Our metabolic expression subtypes
correlated extensively with clinical outcome: sub-
types with upregulated carbohydrate, nucleotide,
and vitamin/cofactor metabolism most consistently
correlated with worse prognosis, whereas subtypes
with upregulated lipid metabolism showed the oppo-
site. Metabolic subtypes correlated with diverse so-
matic drivers but exhibited effects convergent on
cancer hallmark pathways and were modulated by
highly recurrent master regulators across cancer
types. As a proof-of-concept example, we demon-
strated that knockdown of SNAI1 orRUNX1—master
regulators of carbohydrate metabolic subtypes—
modulates metabolic activity and drug sensitivity.
Our study provides a system-level view of metabolic
heterogeneity within and across cancer types and
identifies pathway cross-talk, suggesting related
prognostic, therapeutic, and predictive utility.
INTRODUCTION
Teleologically, cancer cells must modify their metabolic pro-
grams to adapt to the energy and macronutrient requirements
that support rapid proliferation. Indeed, metabolic reprogram-
ming is a well-established hallmark of cancer (Hanahan and
Weinberg, 2011). For example, alterations in carbohydrate meta-
bolism epitomized by the Warburg effect have been recognized
for decades (Vander Heiden et al., 2009). Although different
metabolic functions are known to be perturbed in cancer, studies
of cancer metabolism usually focus on a specific perturbation
and investigate it in isolation for a specific tumor type. However,
metabolic reprogramming in tumor cells is complex, frequently
consisting of alterations in several metabolic functions that syn-
ergize to promote tumorigenesis and cancer cell proliferation.
Elucidating the full spectrum of metabolic reprogramming that
occurs in human cancers will provide key insights into an essen-
tial aspect of tumor development and will also build a basis for
the rational design of cancer treatments that target metabolism.
During carcinogenesis, somatic alterations in oncogenes
and tumor suppressors transform cells by inducing broad
gene expression changes that subsequently cause metabolic
Cell Reports 23, 255–269, April 3, 2018 ª 2018 The Author(s). 255
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Figure 1. The Expression Patterns of Metabolic Pathway Genes Reflect Metabolite Levels in Cancer Patient Samples
(A) The analytic pipeline for assessing whether the expression levels of metabolic pathway genes are correlated with the concentration of a given
metabolite.
(legend continued on next page)
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reprograming (Vander Heiden and DeBerardinis, 2017). Thus,
gene expression represents a molecular dimension of particular
interest in studying cancer metabolism since it bridges between
oncogenic drivers and metabolic phenotypes. Some pioneering
studies have analyzed large-scale gene expression data across
multiple cancer types (Haider et al., 2016; Hu et al., 2013; Nilsson
et al., 2014; Reznik and Sander, 2015). Focusing on comparisons
of tumor and adjacent normal tissue, those studies show
widespread transcriptional dysregulation of metabolic genes.
Although such studies have provided significant insight into
alteredmetabolic pathways of cancer cells, the clinical relevance
of the results may be limited since tumor and normal tissues
usually contain very different cell compositions (e.g., fraction of
epithelial cells). Gaude and Frezza (2016) took a more pertinent,
pathway-focused approach to the analysis of data from clinical
samples and identified several differentially expressedmetabolic
pathways that distinguish patients by clinical outcomes. Those
and many other studies have revealed considerable metabolic
heterogeneity, both within and among cancer types, underscor-
ing the importance of patient stratification in a context-specific
manner. However, it remains unclear how to stratify cancer
patients most effectively into different subtypes (groups) based
on the expression patterns of metabolic genes. More impor-
tantly, the utility of such tumor subtypes in guiding clinical
practice and therapeutic development remains a major ques-
tion. Here, using the comprehensive molecular data recently
compiled in The Cancer Genome Atlas (TCGA) (Weinstein
et al., 2013), we focused on seven metabolic super-pathways
and characterized metabolic expression subtypes in 33 TCGA
cancer types (9,125 samples; Table S1) to address those ques-
tions in a systematic way.
RESULTS
Expression Patterns of Metabolic Genes Reflect
Metabolic Activities in Cancer Patients
To gain an incisive view of metabolic heterogeneity in cancer, we
curated the gene sets of sevenmetabolic super-pathways based
on the latest Reactome annotations (Fabregat et al., 2016).
Included were amino acid metabolism (348 genes), carbohy-
drate metabolism (286 genes), integration of energy (110 genes),
lipid metabolism (766 genes), nucleotide metabolism (90 genes),
tricarboxylic acid cycle (TCA cycle, 148 genes) and vitamin &
cofactor metabolism (168 genes) (Table S2). Those gene sets
are largely independent of each other, with only a few genes of
overlap, and they collectively represent major metabolic
processes.
One key question is whether the expression patterns of meta-
bolic pathway genes reflect actual metabolic activities in pa-
tients. Since data on the metabolites themselves are not avail-
able for TCGA samples, we obtained a published dataset that
contains parallel metabolite profiling and gene expression data
on 60 breast cancer patient samples (Terunuma et al., 2014)
and focused on the 296 metabolites that had been annotated
to 6 out of the 7 metabolic super-pathways that we surveyed.
For each metabolite, we calculated the correlation of its abun-
dance with gene expression levels in the corresponding meta-
bolic pathway, then compared the resultant p value distribution
with the background distribution calculated from other genes
(Figure 1A). In total, we detected 73metabolites that significantly
correlated with the expression of corresponding metabolic
pathway genes (false discovery rate [FDR] < 0.15), including
22 metabolites involved in amino acid metabolism, 22 in carbo-
hydrate metabolism, 21 in nucleotide metabolism, 4 in vitamin &
cofactor metabolism, 2 in integration of energy, and 2 in lipid
metabolism (Figure 1B shows four representative cases from
different pathways; Figure 1C provides the full list of significant
metabolites). To assess the statistical significance of the number
of significant hits detected, we performed a simulation analysis
to compare the number of metabolites with significant signals
from each pathway with those based on random gene sets of
the same size. Strikingly, all six metabolic pathways showed
higher numbers of significant metabolites than expected by
chance (p < 0.05, Figure 1D). For example, the number of signif-
icant carbohydrate metabolites for the real pathway gene set
was 22, whereas the expected number for a random gene set
was only 0.3 (p < 0.001). These results indicate that the expres-
sion patterns of metabolic pathway genes do reflect metabolic
activities.
Classification of Metabolic Expression Subtypes and
Their Overall Similarity
We next aimed to characterize metabolic heterogeneity within
cancer types based on the expression patterns of metabolic
pathway genes. For that purpose, we developed a computa-
tional method to classify tumor samples into ‘‘directional’’ meta-
bolic subtypes in two independent steps (Figure 2A). In the first
step, within each cancer type, we normalized gene expression
across samples by Z score to obtain a rank value for each
gene (18,000 coding genes) within each sample. Then, given
the gene set of a specific metabolic pathway, we conducted
gene set enrichment analysis (GSEA) (Subramanian et al.,
2005) on the resulting rank values to classify tumors into three
subtypes: (1) ‘‘upregulated subtype’’ for the samples in which
metabolic pathway genes showed enrichment with high Z scores
(FDR < 0.25); (2) ‘‘downregulated subtype’’ for samples showing
the opposite pattern (FDR < 0.25); and (3) ‘‘neutral subtype’’ for
samples showing no significant enrichment pattern. Note that
the concept of ‘‘upregulated’’ or ‘‘downregulated’’ here is relative
to other tumors within the same cancer type, rather than relative
(B) Representative quantile-quantile (QQ) plots showing p values (log transformed) from themetabolite-gene Spearman correlation coefficients of pathway genes
compared to other genes. Sarcosine for amino acid metabolism; N-acetylmannosamine for carbohydrate metabolism; 5, 6-dihydrouracil for nucleotide meta-
bolism; nicotinamide adenine dinucleotide for vitamin & cofactor metabolism.
(C) Heatmap showing all metabolites whose intracellular concentrations significantly correlate with the expression levels of the corresponding pathway genes
(FDR < 0.15).
(D) The statistical significance of the numbers of metabolites correlated with the pathway gene expression based on the background distribution of random gene
sets. The red lines indicate the true numbers.
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Figure 2. Classification of Metabolic Expression Subtypes Based on Pathway Gene Expression
(A) The computational method to classify tumor samples into three metabolic expression subtypes: upregulated, downregulated, and neutral. Bar charts
represent the numbers of genes for metabolic pathways surveyed.
(B) Distributions of three metabolic subtypes for each metabolic pathway in 33 cancer types. Only tumor subtype classifications passing the two-step statistical
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to normal tissues. In the second step, we assessed whether the
metabolic genes overall showed differential expression patterns
(FDR < 0.05) among the tumor subtypes defined in the first step,
given thatmetabolic expression subtypeswere expected to cap-
ture the variation in metabolic pathway gene expression. Among
231 cases assessed (7 pathways 3 33 cancer types), 93.9% of
the cases (217) met that criterion and were kept for subsequent
analyses.
Using the method described above for each metabolic
pathway, we classified 9,125 samples into the three subtypes.
Figure 2B shows the relative proportions of those subtypes
across and within cancer types. Figure S1 shows metabolic
genes with the most consistent changes among the subtypes
across cancer types. Based on the subtype information, we
further examined the co-occurrence of expression subtypes of
different metabolic pathways and found that many subtype
combinations occurred at a much higher frequency than ex-
pected by chance (Figure 2C). For example, the most common
subtype combination was those with upregulated amino acid
metabolism, nucleotide metabolism, and TCA cycle. They
showed >10-fold more frequently than expected by chance (Fig-
ure 2D). We compared the similarity of different metabolic sub-
type classifications based on sample-level labels and found
that amino acid metabolism, TCA cycle, and nucleotide meta-
bolism formed one tight cluster, whereas integration of energy,
carbohydrate metabolism, lipid metabolism, and vitamin &
cofactor metabolism formed another distinct cluster (Figure 2E).
These results provide a global view of the similarity of different
metabolic pathways and may reflect crosstalk among them.
Metabolic Expression Subtypes Show Extensive
Clinically Relevant Patterns
To assess the clinical relevance of themetabolic expression sub-
types identified above, we next determined correlations with pa-
tient overall survival, since survival represents a key clinical index
of tumor aggressiveness. Figure 3A is a summary of 33 signifi-
cant survival associations for the metabolic subtypes in 27 can-
cer types that included sufficient sample size and follow-up time
(log-rank test, FDR < 0.2, 28 associations remained significant
after adjusting for tumor purity). Notably, upregulated subtypes
of carbohydrate, nucleotide, and vitamin & cofactor metabolism
were consistently associated with poor prognosis (Figure 3B),
compatible with the hypothesis that cancer cells have increased
demands for glucose uptake and nucleotide synthesis (Pavlova
and Thompson, 2016; Vander Heiden and DeBerardinis, 2017).
Unexpectedly, upregulated TCA cycle and lipid metabolic sub-
types were associated with better prognosis (Figure 3C). Amino
acidmetabolism and energy integration subtypes showedmixed
patterns. We obtained similar results using univariate Cox
regressionmodels (Figure S2). The consistent association of sur-
vival patterns with certain metabolic subtypes (e.g., carbohy-
drate metabolism) across cancer types suggests that metabolic
subtyping has potential prognostic value.
Among the cancer types surveyed, low-grade glioma (LGG)
exhibited the most extensive survival correlations (5 out of
the 7 metabolic pathways; Figure S3). For LGG, poor prognosis
was significantly associated with downregulated subtypes of
amino acid metabolism, energy integration, and TCA cycle but
with upregulated subtypes of carbohydrate and vitamin &
cofactor metabolism. LGGs have mutations of isocitrate dehy-
drogenase 1 (IDH1) in >70% of cases and mutations of IDH2 in
a minority of cases. IDH1 and IDH2 mutations are activating for
production of high levels of the oncometabolite 2-hydroxygluta-
rate (2HG) from alpha-ketoglutarate (Claus et al., 2015; Dang
et al., 2009;Ward et al., 2010). The extensive prognostic patterns
observed support the notion of glioma as a disease influenced by
metabolism.
Genomic profiling studies, especially recent TCGA studies,
have characterized a number of tumor subtypes that capture
major patterns of within-disease heterogeneity. Those tumor
subtypes are informative about cancer pathophysiology and, in
some cases, for clinical decisionmaking.We therefore examined
the correlations between metabolic expression subtypes and
previously established molecular tumor subtypes and detected
many significant correlations (Figure S4). For example, in breast
invasive carcinoma (BRCA), we found that the vast majority of
cases in which nucleotide metabolism was downregulated
belonged to the luminal A (lumA) subtype (Sørlie et al., 2001);
in esophageal carcinoma (ESCA), cases with upregulated lipid
and vitamin & cofactor metabolismwere enriched in the chromo-
somal instability subtype (CIN) (Cancer Genome Atlas Research
Network, 2017); in glioblastoma multiforme (GBM), cases of
downregulated lipid metabolism were enriched in the IDHmut-
non-codel subtype (Eckel-Passow et al., 2015); in head-neck
squamous cell carcinoma (HNSC), cases with downregulated
carbohydrate metabolism were enriched in the HPV subtype
(Figure 3C). These results highlight the clinical relevance of
metabolic expression subtypes presented here and provide an
informative metric for defining tumor heterogeneity.
Metabolic Expression Subtypes Are Associated with
Diverse Somatic Drivers but Convergent Pathway
Functional Effects
Metabolic reprogramming can be largely viewed as a conse-
quence of oncogenic driver events (DeBerardinis and Chandel,
2016). For example, mutated TP53 and MYC amplification
have been extensively linked to anabolic or catabolic activities,
including glycolysis and redox balance in cancer (Kruiswijk
et al., 2015; Stine et al., 2015). To identify somatic alterations
that potentially drive metabolic expression subtypes, we per-
formed a correlation analysis of metabolic expression subtypes
with mutation driver genes. For each cancer type, we identified
(C) Frequency distribution of a specific metabolic subtype combination. The red line is for the observed distribution; black lines are for the random expectation
assuming that each metabolic pathway is perturbed independently in a tumor sample.
(D) The top 10 most frequently observed metabolic subtype combinations. Red, upregulated subtype; gray, neutral subtype; and blue, downregulated subtype.
The right panel indicates the observed and expected frequencies of a specific subtype combination. Data are represented as mean ± SD. *p < 0.05, ***p < 0.001.
(E) Clustering pattern of the seven metabolic subtypes based on the similarity of subtype labels across 9,125 samples.
See also Table S1, Table S2, and Figure S1.
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significantly mutated genes (SMGs, identified byMutSigCV, with
amutation frequency >5%) (Lawrence et al., 2013) and assessed
whether their mutation status correlated with metabolic sub-
types. We found 31 associated SMGs (chi-square test, FDR <
0.05), and their associated patterns were quite diverse across
cancer types (Figure 4A). The SMGs identified recurrent across
multiple cancer types included TP53 (9 cancer types), PIK3CA
(4 cancer types), KRAS (3 cancer types), CDH1 (2 cancer types),
CTNNB1 (2 cancer types), EGFR (2 cancer types), HRAS (2 can-
cer types), IDH1 (2 cancer types), KEAP1 (2 cancer types), and
NFE2L2 (2 cancer types). Figure 4B shows the metabolic sub-
type correlations with mutated TP53 as an example. Similarly,
we examined the correlations of metabolic expression subtypes
with potential drivers of somatic copy number alteration (SCNA).
For each cancer type, we identified amplified oncogenes or
deleted tumor suppressors in SCNA peaks (identified by GI-
SITC2, FDR < 0.25) (Mermel et al., 2011) and assessed whether
their copy number status correlated with a metabolic subtype
(chi-square test, FDR < 0.05). We identified 35 such drivers.
Some of them showed correlations with multiple metabolic sub-
types in several cancer types, includingARID1A (8 cancer types),
MYC (7 cancer types), CDKN2A (6 cancer types), EGFR (5 can-
cer types), PARK2 (5 cancer types), RB1 (4 cancer types),
PTEN (4 cancer types), AKT1 (4 cancer types), BCL2L1 (4 cancer
types), and SOX2 (4 cancer types; Figure 4C). Figure 4D shows
the subtype correlations with amplified MYC as an example.
These analyses provide a broad view of potential somatic drivers
associated with metabolic reprogramming in human cancer.
To assess further the biological relevance ofmetabolic expres-
sion subtypes, we examined their associations with various
cellular pathways by GSEA based on mRNA expression (FDR <
0.01, Figure 4E). That analysis included six functional cancer hall-
marks (i.e., angiogenesis, apoptosis, DNA repair, epithelial–
mesenchymal transition [EMT], G2M checkpoint, and inflamma-
tory response) and also the mTORC1 signaling pathway, which
has been implicated in metabolic dysregulation and cancer
development (Hay, 2016) (STARMethods). Interestingly, despite
the diversity of cancer types surveyed, we found that pathway-
level functional effects associated with each kind of metabolic
subtype were largely consistent across cancer types. Among
the seven metabolic expression subtypes, amino acid meta-
bolism, nucleotide metabolism, and TCA cycle exhibited the
most similar profiles. Their upregulated subtypes were consis-
tently associated with increased DNA repair, decreased angio-
genesis, decreased EMT, and decreased inflammation (Fig-
ure 4E). Angiogenesis, EMT, and inflammation were positively
correlated with upregulated carbohydrate metabolism and inte-
gration of energy and, to a lesser degree, upregulated lipid meta-
bolism andmetabolism of vitamins & cofactors. G2M checkpoint
was consistently negatively correlated with the energy and lipid
metabolism subtypes. DNA repair was inversely correlated with
energy integration and lipid metabolism. Interestingly, mTORC1
signaling was generally increased for all of the metabolic sub-
types except energy integration, consistent with the central role
of mTORC1 signaling in regulating cancer metabolism. Overall,
these results suggest that metabolic activity is intrinsically
coupled with cancer hallmark pathways.
Highly Recurrent Master Regulators for Metabolic
Subtypes across Cancer Types
To elucidate how the metabolic expression subtypes are regu-
lated, we performed computational analyses to identify two types
of ‘‘master regulators’’: transcription factors (TFs) and miRNAs
(STAR Methods). For TFs (Figure 5A), we first inferred tumor-
context-specific gene regulatory networks based on the cancer-
type-specific expression data, using the algorithm for reconstruc-
tion of accurate cellular networks (ARACNe) (Lachmann et al.,
2016).We thenemployed themaster regulator inferencealgorithm
(MARINa) and the shadow analysis (Aytes et al., 2014; Lefebvre
et al., 2010) to infer the master TFs for each metabolic pathway
in each cancer type. The analysis revealed many highly recurrent
TFs for the same metabolic pathway across different cancer
types. Among different metabolic subtypes, amino acid meta-
bolism, nucleotide metabolism, and TCA cycle shared a large
number of master TFs across many cancer types (Figure 5B).
For miRNAs, we used two criteria to identify master regulators:
(1) the miRNA targets are significantly enriched in differentially
expressed genes between upregulated and downregulated sub-
types and (2) the miRNAs themselves show significant corre-
sponding changes between the two subtypes (STAR Methods).
We found that many miRNA master regulators recurred across
cancer types. miR-484, miR-107, miR-320a, and miR-429 ap-
peared to be the strongest regulators of themetabolism of amino
acids, nucleotides, carbohydrates, and vitamins & cofactors.
Interestingly, the latter three miRNAs have been reported to be
key regulators of cancer metabolism (Chan et al., 2015; Rottiers
and Na¨a¨r, 2012) (Figure 5C). Further examination revealed that
SCNAs can modulate the expression of some regulators, such
as miR-320a in stomach adenocarcinoma (STAD) for nucleotide
metabolic expression subtypes (Figure 5D).
A Systematic View of Altered Metabolism in Cancer
Integrating insights from the above analyses, a systematic view
of heterogeneous metabolic activity in cancer has emerged
Figure 3. Associations of Metabolic Expression Subtypes with Patient Survival Times and Tumor Subtypes
(A) Clinical associations of metabolic expression subtypes with patient overall survival times. Color indicates the correlation direction; significant correlations
(log-rank test, FDR < 0.2) are boxed. Those cases without qualified subtype classifications are left in blank.
(B) Kaplan-Meier plots for carbohydrate metabolic expression subtypes associated with patient overall survival times in head and neck squamous cell carcinoma
(HNSC), low-grade glioma (LGG), lung adenocarcinoma (LUAD), and sarcoma (SARC).
(C) Kaplan-Meier plots for lipid metabolic expression subtypes associated with patient overall survival times in adrenocortical carcinoma (ACC), colon adeno-
carcinoma (COAD), kidney renal clear cell carcinoma (KIRC), and liver hepatocellular carcinoma (LIHC). Cancer type, metabolic expression subtype, and the p
value of log-rank test are shown at the top of each plot.
(D) Representative examples of associations between metabolic expression subtypes and established tumor subtypes. p values are based on chi-square test.
See also Figures S2–S4.
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(Figure 6A). Metabolic reprogramming may result from diverse
somatic driver alterations in different tumor contexts, but it ap-
pears to converge on common pathway-level functional effects
through modulation of highly recurrent master regulators across
cancer types, ultimately leading to consistent survival patterns.
According to this model, the master TFs identified here are key
nodes with the greatest influence on systems-level metabolic
activities. Therefore, those TFs may represent a class of thera-
peutic targets whose inhibition could potentially yield clinical
benefits.
To test that hypothesis, we focused on carbohydrate meta-
bolism, since its upregulated subtypes showed the most consis-
tently poor prognostic patterns across cancer types (Figures 3A
and 3B). To be an ideal target, a master TF should bemore highly
expressed in the subtype with worse prognosis so that inhibition
and subsequent downregulation of the target could confer
enhancedsurvival. Among the8cancer typeswhoseupregulated
carbohydrate subtypes had significantly worse survival rates,
fourmaster TFs,SNAI1,RUNX1,RUNX2, and FOSL1, were iden-
tified in at least three cancer types (Figure 6B).Wechose twoTFs,
SNAI1 and RUNX1, to perform experimental perturbation. Fig-
ures 6Cand6Dshowhigher expression levels of those twogenes
in the upregulated subtypes in lung adenocarcinoma (LUAD) and
sarcoma (SARC), respectively. Using shRNAs,we knockeddown
the expression ofSNAI1 in a lung cancer cell line, NCIH1975, and
RUNX1 in a sarcoma cell line, U2OS (Figure S5, Table S3). We
then measured the relative abundance of intracellular glucose
(amodel carbohydrate) using high-resolutionmass spectrometry
at time points of 0 h, 6 h, and 24 h. The concentrations of intracel-
lular glucose were significantly decreased in the knockdown cell
lines (Figure 6 E and F, paired t test, p < 0.05), suggesting that
SNAI1 and RUNX1 indeed positively modulate carbohydrate
metabolism. Further studies with more robust controls will be
required to validate the proposed effects in terms of whether
the knockdown affects glucose transporter expression and
whether the knockdown has predicted effects on carbohydrate
metabolic gene expression.
Metabolic Expression Subtypes Are Informative About
Drug Sensitivity
To explore further the potential clinical utility of carbohydrate
metabolic expression subtypes, we used expression and drug
sensitivity data from Cancer Cell Line Encyclopedia (CCLE) (Bar-
retina et al., 2012; Iorio et al., 2016). We focused on 181 lung
cancer cell lines because of the sufficient sample size for sub-
type classification. Using the same bioinformatic methods as
describedabove,weclassified34, 33, and114cell linesasdown-
regulated, upregulated, and neutral subtypes, respectively. We
next compared themolecular characteristics associatedwith up-
regulated subtypes of patient samples and cell lines. EGFR—the
most important therapeutic target in lung cancer—was identified
as a SCNA driver associated with carbohydrate metabolic
expression subtypes of patient samples. It showed significantly
higher copy-number and mRNA expression levels in the upregu-
lated carbohydrate subtype than in the downregulated subtype
(Figure S6A). Concordantly, the carbohydrate expression sub-
types of lung cancer cell lines adhered to that pattern (Fig-
ure S6B). Furthermore, the cell lines in the upregulated subtype
had higher proliferation rates than those from the downregulated
subtype (Figure S6C), consistent with the observation that LUAD
patients in the upregulated carbohydrate metabolic subtype
exhibited worse prognosis (Figure 3B) (Haverty et al., 2016).
These results independently validate the patterns observed in
TCGA patient samples, suggesting that the analyses are robust.
Given the three carbohydrate expression subtypes of lung
cancer cell lines, we found that 12 drugs showed significantly
different sensitivities (Figure 7A, FDR < 0.05). Among those
drugs, docetaxel is a chemotherapy drug currently used for pa-
tients with lung cancer. Cell lines in the carbohydrate-upregu-
lated subtype were more sensitive to docetaxel than cell lines
in other subtypes (Figure 7B). To test further the effect of carbo-
hydrate metabolism on drug sensitivity, we assessed the sensi-
tivity of lung cancer cell line NCIH1975 (classified as upregulated
subtype) to knockdown of SNAI1, since that perturbation has
been found to modulate carbohydrate metabolism negatively.
Indeed, compared with the negative control (scrambled shRNA),
the SNAI1-KD cell line was more resistant to docetaxel, and
that pattern was consistently observed at both 16 hr and 24 hr
after treatment (Figures 7C and 7D). The results suggest that
LUAD patients with high carbohydrate metabolic activities may
be more likely to benefit from docetaxel treatment.
DISCUSSION
Metabolic reprogramming is considered one of the hallmarks
of cancer (Hanahan and Weinberg, 2011; Ward and Thompson,
Figure 4. Somatic Drivers and Biological Pathways Associated with Metabolic Expression Subtypes
(A) Somatic mutation drivers associated with metabolic expression subtypes. For each cancer type, the mutational status of significantly mutated genes
(identified by MutSigCV, with a mutation frequency > 5%) were assessed based on chi-square test. Colors in each circle indicate the correlations with different
kinds of metabolic expression subtypes.
(B) Correlations of metabolic expression subtypes with TP53mutation status. The inner band indicates the mutation status of TP53 (dark red, mutated; light red,
wide-type); external bands indicate the subtype information of a specific metabolic pathway (red, upregulated; gray, neutral; and blue, downregulated).
(C) Somatic copy number alteration drivers associated with metabolic expression subtypes. For each cancer type, the copy number status of known oncogenes
or tumor suppressors residing in a significant amplification for deletion peak (identified by GISTIC2) were assessed based on chi-square test.
(D) Correlations of metabolic expression subtypes withMYC amplification status. The inner band indicates the amplification status ofMYC (dark red, high-level
amplification; light red, low-level amplification); external bands indicate the subtype information of a specific metabolic pathway (red, upregulated; gray, neutral;
and blue, downregulated). In (A) and (C), only associations with FDR < 0.05 are shown; color indicates the specific associated metabolic pathway.
(E) Correlations of metabolic expression subtypes with six cancer hallmarks and mTOR signaling pathway based on GSEA (the related gene sets are based on
MSigDB). Those cases without qualified subtype classifications are left in blank, and significant enrichments (FDR < 0.01) are colored in red or blue. For the
analysis, differentially expressed genes were identified between the upregulated and downregulated subtypes. Red indicates the enrichment of a hallmark gene
set in genes highly expressed in the upregulated metabolic expression subtype; blue indicates the opposite pattern.
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2012). Because metabolism is so complex, there is a need
for systematic characterization. Several previous studies have
demonstrated considerable heterogeneity in the expression of
genes involved in various metabolic functional pathways (Gaude
and Frezza, 2016; Haider et al., 2016; Hu et al., 2013; Nilsson
et al., 2014; Reznik and Sander, 2015). Based on a breast cancer
patient cohort with parallel metabolite and transcriptomic
profiling data (Terunuma et al., 2014), we demonstrated that
the expression patterns of metabolic pathways indeed reflect
metabolic activities. Metabolite profiling has recently become
an informative approach to elucidate tumor heterogeneity
(Hakimi et al., 2016). Similar analyses should extend to more
patient cohorts to further validate our findings when such data
are available.
The expression patterns analyzed in previous studies ranged
from global to discrete (i.e., affecting particular metabolic path-
ways). Here, we have focused on effective stratification of can-
cers based on the expression heterogeneity of metabolic genes
within cancer types. One central aim is to define meaningful
metabolic expression subtypes. Our computational method,
which combines GSEA and self-contained gene set analysis,
has two advantages: (1) it allows consistent classification of tu-
mor subtypes, facilitating comparison and contrast across a
broad range of cancer types and (2) it classifies tumor samples
according to ‘‘functional state’’ of a specific metabolic process
(upregulated, neutral, or downregulated), facilitating interpreta-
tion of downstream analyses. Through that systematic classifi-
cation, we found that metabolic expression subtypes frequently
correlate with each other. In particular, metabolic perturbations
of amino acids, nucleotides, and TCA cycle are strongly coupled,
as demonstrated by high correlations of their subtype assign-
ment, similar pathway-level associations, and shared master
regulators. That global perspective has not been presented
previously. Another feature of the present study is that, by
integrating TCGA multidimensional molecular data on the
same sample cohorts, we have identified potential drivers and
master regulators associated with the metabolic derangements
observed in our global analysis. While the driver roles of some
alterations identified in affecting metabolism such as TP53
mutation andMYC amplification have been documented, further
efforts will be required to validate the causal relationships of
others.
The metabolic expression subtypes defined here have poten-
tial clinical implications. First, we demonstrate the extensive cor-
relations of metabolic expression subtypes with prognosis
across cancer types, suggesting that the subtypes reflect essen-
tial aspects of tumor development. Notably, different metabolic
expression subtypes showed distinct patterns. The upregulated
subtypes of carbohydrates, nucleotides, and vitamins & cofac-
tors were associated with worse prognosis, whereas lipid meta-
bolism showed the opposite association. Regardless of underly-
ing reasons, that observation suggests a more complex
relationship betweenmetabolic reprogramming and cell prolifer-
ation than usually assumed. Second, using CCLE data, we
demonstrate that the metabolic subtypes correlate with sensi-
tivity to drugs used in the clinic, highlighting the possibility that
metabolic status will sometimes be important to consider in se-
lection of a treatment regime. Overall, the results here support
the potential utility of metabolic expression subtypes as prog-
nostic and predictive markers.
Since metabolic reprogramming is an essential aspect of
tumorigenesis and cancer cell proliferation, inhibition of meta-
bolic functions may inhibit tumor progression. Current strate-
gies for considering the effect of metabolism on therapy focus
on functionally important metabolic isoenzymes that show
cancer-specific somatic or expression changes. There have
been a number of studies along those lines (Vander Heiden
and DeBerardinis, 2017), but targeting of metabolic genes for
therapy has had only very limited success (Vander Heiden
and DeBerardinis, 2017). Our systems-biological analysis sug-
gests a generic therapeutic strategy. For upregulated meta-
bolic subtypes that are consistently associated with worse
patient prognosis, tumors may be vulnerable to a therapy, or
component of combination therapy, that targets their master
regulatory factors. Inhibiting responsible master regulators
has the potential to convert the upregulated subtype to
the downregulated subtype, thereby conferring a survival
benefit. Our functional validation results provide preliminary
but exciting evidence supporting that hypothesis, and further
studies will be required.
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(B) Network view of ‘‘master’’ transcription factors associated with metabolic expression subtype. The line thickness indicates the number of cancer types where
the connection was identified. Only the connections identified inR3 cancer types are shown.
(C) Network view of ‘‘master’’ miRNA regulators.
(D) MiRNA hsa-miR-320a identified as a master regulator for expression subtypes of the nucleotide metabolism pathway in stomach adenocarcinoma (STAD).
SCNAs of hsa-miR-320a lead to a lower expression in the samples of downregulated subtype. Its target genes are significantly enriched in genes highly
expressed in the downregulated subtype. The middle line in the box is the median, and the bottom and top of the box are the first and third quartiles, and the
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Figure 6. Effects of Master Regulators on Carbohydrate Metabolism
(A) Systematic view of metabolic reprogramming across cancer types.
(B) The network shows that master TFs for carbohydrate metabolism identified in R3 cancer types whose upregulated subtypes showed significant worse
prognosis, and these master regulators haveR150 target genes and higher expression levels in the upregulated subtypes.
(C and D) Master regulator expression level in three carbohydrate metabolic expression subtypes: SNAI1 in lung adenocarcinoma (LUAD) (C) and RUNX1
in sarcoma (SARC) (D). The middle line in the box is the median, and the bottom and top of the box are the first and third quartiles, and the whiskers extend to
1.53 interquartile range of the lower quartile and the upper quartile, respectively.
(E and F) Relative abundance of intracellular glucose in the NCIH1975 cell line (control) and the cell line with shRNA-mediated SNAI1 knockdown (E) and in the
U2OS cell line (control) and the cell line with shRNA-mediated RUNX1 knockdown (F) at three time points (0 hr, 6 hr, and 24 hr). p value was based on paired t test.
See also Figure S5 and Table S3.
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Figure 7. Carbohydrate Expression Subtypes Are Informative about Drug Sensitivity
(A) Heatmap showing drug sensitivity variation across lung cancer cell lines. Those lung cancer cell lines were classified into downregulated, neutral, and
upregulated carbohydrate metabolic subtypes using the same method as for TCGA patient samples. All the drugs with a significant difference of IC50 (log-
transformed) among the three subtypes (FDR < 0.05) are shown.
(B) The distributions showing the log-transformed IC50 values of docetaxel in the carbohydrate metabolic expression subtypes.
(C and D) The effect of SNAI1 knockdown in NCIH1975 cells on drug response of docetaxel at 16 hr (C) and 24 hr (D). Data are represented as mean ± SE.
Compared to negative control (scrambled shRNA), *p < 0.05.
See also Figure S6.
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(hliang1@mdanderson.org).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
The NCIH1975 cell line was a generous gift from Dr. Zahid H. Siddik’s laboratory at MD Anderson Cancer Center. HEK293LTX and
U2OS cell lines were obtained fromMD Anderson Characterized Cell Line Core Facility. All cell lines were confirmed by short tandem
repeat (STR) analysis and were negative for mycoplasma contamination prior to use. NCIH1975 cells were cultured in RPMI 1640
medium supplemented with 10% fetal bovine serum. U2OS cells were maintained in DMEM with L-glutamine, 4.5 g/L glucose,
sodium pyruvate and 10% fetal bovine serum.
METHOD DETAILS
Analysis of metabolic pathway genes and metabolite profiling data in breast cancer samples
We obtained metabolite profiling data and mRNA expression data on 60 breast cancer patients (Terunuma et al., 2014). We focused
the 296 metabolites that had been annotated to the 6 metabolic super pathways including 88 in amino acid, 38 in carbohydrate,
9 in integration of energy, 116 in lipid metabolism, 26 in nucleotide, and 19 in vitamin & cofactor metabolism. For each metabolite,
we calculated the Spearman rank correlations between its abundance and the expression levels of the genes in the corresponding
pathway. Then we compared the empirical cumulative distributions of p values from pathway genes versus other genes using
Kolmogorov-Smirnov test. One-tailed test was used to test whether the p values of the pathway gene set were more significant
than those of other genes at FDR < 0.15. To evaluate whether pathway genes are more informative about metabolic activities
than other gene sets, we performed a simulation analysis. We randomly selected a gene set with the same size of a metabolic
pathway and identified the number of metabolites significantly correlated with the expression of the gene set in the same way as
the metabolic pathway genes. We repeated this analysis for 1,000 times to generate the background distribution of significant
hits from which we assessed the observed numbers were statistically higher than random expectation.
Metabolic expression subtype classification
Considering the heterogeneity of the metabolic pathway dysregulation in tumors, we developed an algorithm to classify individual
tumors given the gene set of each metabolic pathway. For a specific patient, the classification was based on the deviation extent
of the expression level of genes in a metabolic functional pathway from the average values of the cohort relative to other genes.
For each of the 33 cancer types, Z-normalization was performed per gene across samples. Then, the genes were ranked by Z scores
per sample. GSEA pre-ranked analysis was used to determine whether the genes from ametabolic pathway were enriched at the top
or bottom of the pre-ranked gene list for each sample. For a specific pathway, a tumor sample was classified into one of three distinct
groups at FDR < 0.25: ‘‘upregulated,’’ ‘‘downregulated,’’ or ‘‘neutral.’’ Then we performed self-contained gene analysis to confirm
each subtype classification. Given themetabolic expression subtypes, we first evaluated expression differentiation of protein-coding
genes using ANOVA and then used the Kolmogorov-Smirnov test to determine whether the p values of the pathway genes were
lower than those from other genes (FDR < 0.05). Through this systematic analysis, each tumor sample was labeled with seven kinds
of metabolic expression subtypes. To determine the mutual dependence among those seven classifications, mutual information was
calculated using the R package ‘‘entropy.’’ After normalizing the mutual information by dividing the maximum value for each row, the
mutual information distance was calculated as 1- mutual information.
Clinical relevance analysis of metabolic expression subtypes
We evaluated the correlations of metabolic expression subtypes with two clinical features respectively: the patients’ overall survival
time and established molecular subtype. The R package ‘‘survival’’ was used to perform the overall survival analysis and produce
Kaplan-Meier survival plots. A log-rank test was used to assess the significance (FDR < 0.2). For significant survival associations,
we further assessed whether the subtypes correlated with tumor purity using ANOVA or whether the survival correlations remained
significant after including tumor purity as covariate in Coxmodel. As formolecular subtype analysis, chi-square test was performed to
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
ssmarina (Aytes et al., 2014; Lefebvre et al., 2010) https://figshare.com/articles/
ssmarina_R_system_package/785718
Thermo TraceFinder ThermoFisher Scientific https://www.thermofisher.com/
order/catalog/product/OPTON-30491
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access the correlation between tumor subtypes and metabolic expression subtypes (assigned to one of three values, 1, 0, or 1,
FDR < 0.05).
Somatic driver association analysis
To identify oncogenic events that potentially drive metabolic reprogramming, we analyzed the associations of mutation drivers and
SCNA drivers with metabolic expression subtypes in each cancer type. For the mutation analysis, we first excluded 314 hypermu-
tated samples, and only focused on the significantly mutated genes (identified by MutSigCV 1.4, FDR < 0.25) (Lawrence et al., 2013)
with a mutation frequency > 5% for each cancer type. We performed chi-square test to determine the association between the
metabolic expression subtypes and a specific mutated gene status, and reported the significance at FDR < 0.05. For the SCNA anal-
ysis, we assessed the copy number status of known oncogenes or tumor suppressors (Zack et al., 2013) residing in a significant
amplification or deletion peak identified by GISTIC2 (Mermel et al., 2011) in each cancer type by chi-square test (FDR < 0.05).
Biological pathway association analysis
To explore the biological processes responsible for the metabolic reprogramming, we analyzed the correlations between metabolic
expression subtypes with cancer hallmark pathways in each cancer type. The log2 transformed RNA-seq data were used. The seven
selected cancer hallmark pathways were angiogenesis, apoptosis, DNA repair, EMT, G2M checkpoint, inflammatory response and
mTORC1 signaling, and the related gene sets were obtained from MSigDB (http://software.broadinstitute.org/gsea/msigdb). We
used Student’s t tests between upregulated and downregulated subtypes to generate ranked gene lists for each cancer type.
Then, pre-ranked GSEA analysis were used to determine the pathway enrichment or depletion (FDR < 0.01).
Master regulator analysis
To identify TF master regulators, we first inferred the tumor-context-specific GRNs with the expression data (Z score transformed)
from all tumor samples using ARACNe-AP, which is a new Java implementation of the ARACNe (Lachmann et al., 2016). Our analysis
used the list of transcription factors as previously described (Vaquerizas et al., 2009). Then, given the inferred networks, we used the
MARINa (R package ssmarina) to infer master regulators based on the comparison of expression between upregulated and down-
regulated samples for each metabolic expression subtype in each cancer type and performed the shadow analysis to all master reg-
ulators identified with p < 0.05 (Aytes et al., 2014; Lefebvre et al., 2010). We identified master TFs as those passing the shadow anal-
ysis (FDR < 0.1) and havingR 150 target genes. To identify miRNAmaster regulators, we used two criteria: (1) the expression level of
themicroRNA itself showed a significant difference between the two groups (fold-change > 1.2 and p value < 0.01); and (2) themiRNA
target genes that showed differential expression between upregulation and downregulation subtypes were prone to being commonly
regulated by a specific microRNA (FDR < 0.1). GSEA (including annotated miRNA target gene sets) was employed for this analysis
(Subramanian et al., 2005); and the differential direction of the microRNA should be opposite to the expression of the corresponding
target gene set. The network of master regulators andmetabolic subtypes were analyzed by Cytoscape (Shannon et al., 2003). In the
TF networks, each link represented a specific TF identified in at least 3 cancer types. As for miRNA, a link represented a specific
microRNA identified in at least one cancer type.
Analysis of CCLE data
We downloaded RNaseq-based expression data and gene-level copy number from Cancer Cell Line Encyclopedia (CCLE; https://
portals.broadinstitute.org/ccle) and focused on 181 lung cancer cell lines with gene expression data. Using the same classification
pipeline, we classified them into downregulated, neutral, and upregulated subtypes based on the expression levels from the
carbohydrate pathway. We obtained the drug screening data from Iorio et al. (2016). We performed ANNOVA analysis to determine
whether (log-transformed) IC50 values showed significant difference among the three carbohydrate expression subtypes of cell lines
(FDR < 0.05). We obtained the doubling time data of cancer cell lines from Haverty et al. (2016). We used Wilcoxon rank sum test to
assess whether the doubling time showed a significant difference between carbohydrate downregulated and upregulated subtypes.
Generation of stable cell lines
Lentiviruses were produced by co-transfection HEK293LTX cells with the MISSION TRC2 pLKO.5-puro Non-Mammalian shRNA
Control Plasmid DNA orwith the pLKO-puro shRNA constructs (Sigma, shRNA sequences are available in Table S3) and the Lentiviral
Packaging Mix (psPAX2 and pMD2.G). U2OS and NCIH1975 cells were transduced by the lentivirus, and cells with stable knock-
downs were selected using puromycin (2 mg/ml for U2OS and 1 mg/ml for NCIH1975). The knockdown of RUNX1 and SNAI1 in stable
cell lines was confirmed by quantitative real-time PCR.
RNA isolation and quantitative real-time PCR
To examine the effect of the knockdown on potential target genes, total RNA was isolated using the RNeasy Plus Mini Kit (QIAGEN,
Hilden, Germany) and transcribed into cDNA using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, CA,
USA). Reactionswere performed in triplicates using the SYBRSelectMasterMix (Applied Biosystems) and specific primers (Sigma,
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sequences are available in Table S3). RT-qPCR was performed on an Applied Biosystems 7900HT Fast Real-Time PCR
system (Applied Biosystems). The gene expression levels were normalized to b-actin, and relative expression was calculated by
the 2(–DDCt) method.
Glucose measurement by IC-HRMS
We measured the intracellular abundance of glucose in cell samples using high-resolution mass spectrometry (HRMS) as follows.
Cells were seeded in 10 cm dishes and incubated in fresh medium (DMEM or RPMI-1640 containing 10% or 5% FBS, respectively)
for 0 hr, 6 hr, and 24 hr. Before conducting cell extraction, media samples were collected, flash frozen using liquid nitrogen, and trans-
ferred to80C freezer until analysis. Cells were then quickly washed with ice-cold PBS flowed byMilli-Q water to remove extra salt/
medium components. Metabolites were then extracted by adding 500 mL 1% formic acid in 90/10 (v/v) acetonitrile/water. Cell and
medium extracts were then centrifuged at 17,000 g for 5min at 4C, and supernatants were transferred to clean tubes. Samples were
evaporated to dryness using a SpeedVac. Samples were reconstituted in deionized water, then 10 mL was injected into a Thermo
Scientific Dionex ICS-5000+ capillary ion chromatography (IC) system containing a Thermo IonPac AS11 2503 2 mmwith 4 mmpar-
ticle size. IC flow rate was 300 ml/min (at 30C) and the gradient conditions were as follows: initial 1 mM KOH, increased to 35 mM
at 25 min, then to 99 mM at 39 min, held 99 mM for 10 min. The total run time was 50 min. Methanol containing 2 mM acetic acid
was delivered by an external pump and mixed with the eluent. Data were acquired using a Thermo Orbitrap Fusion Tribrid Mass
Spectrometer under ESI negative mode. Thermo Trace Finder software was used for metabolite identification and area integration.
The abundance of glucose was normalized by dividing the area of each metabolite by the total signal (summed areas of all
metabolites) for each sample.
Drug sensitivity assays
To assess changes in drug sensitivity following SNAI1 knockdown, stable cells (1,500 per well) were seeded in 96-well plates in the
complete medium a day before treatment. A 2 mM stock solution of docetaxel (ENZO, New York, USA) was prepared in DMSO and
was further diluted in complete medium to obtain eight serial dilutions such that the final treatment concentrations ranged from
0–2 mM. SNAIL-KD cells and the negative control (scrambled shRNA) cells were treated with DMSO or the various docetaxel dilutions
and cell viability was determined using live imaging (Incucyte Zoom, Essen Biosciences). Phase contrast images (4x objective) were
recorded at 0 hr, 16 hr and 24 hr after treatment initiation and the percentage confluence (a measure of cell viability) was assessed
using the associated software as per manufacturer’s instructions. Relative viability was normalized to the confluence value treated
with DSMO. Docetaxel treatment was repeated independently to ensure reproducibility of the results. The Student’s t test was used
to analyze differences, and p < 0.05 was considered statistically significant.
QUANTIFICATION AND STATISTICAL ANALYSIS
All the analyses were based on 9,125 tumor samples except for miRNA (7,939) due to limited data availability. Definition of signifi-
cance of various statistical tests were described and referenced in their respective Method Details sections.
DATA AND SOFTWARE AVAILABILITY
The raw data, processed data and clinical data can be found at the legacy archive of the GDC (https://portal.gdc.cancer.gov/
legacy-archive/search/f) and the PancanAtlas publication page (https://gdc.cancer.gov/about-data/publications/pancanatlas).
The mutation data can be found here (https://gdc.cancer.gov/about-data/publications/mc3-2017). TCGA data can also be explored
through the Broad Institute FireBrowse portal (http://gdac.broadinstitute.org) and the Memorial Sloan Kettering Cancer Center
cBioPortal (http://www.cbioportal.org). Details for software availability are in the Key Resource Tables.
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